Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations
Conditions: Advanced Malignant Solid Neoplasm; BRAF NP_004324.2:p.V600X; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Histiocytosis; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Stage III Childhood Non-Hodgkin Lymphoma; Stage IV Childhood Non-Hodgkin Lymphoma; Wilms Tumor Interventions: Other: Laboratory Biomarker Analysis; Drug: Vemurafenib Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Brain | Brain Tumor | Cancer & Oncology | Childhood Cancer | Ependymoma | Glioma | Hepatoblastoma | Histiocytosis | Lymphoma | Neuroblastoma | Neurology | Non-Hodgkin's Lymphoma | Osteosarcoma | Pediatrics | Research | Rhabdomyosarcoma | Sarcomas